Arcellx (ACLX) EPS (Weighted Average and Diluted) (2021 - 2025)
Arcellx (ACLX) recorded quarterly EPS (Weighted Average and Diluted) of -$1.01 in Q4 2025, down 2.02% quarter-over-quarter from -$0.99 in Q3 2025, and down 16.09% on a YoY basis from -$1.2 in Q4 2024.
Arcellx (ACLX) EPS (Weighted Average and Diluted) (2021 - 2025) Analysis & Trends
Arcellx's EPS (Weighted Average and Diluted) history runs 5 years deep, the most recent figure standing at -$1.01 for Q4 2025.
- In Q4 2025, EPS (Weighted Average and Diluted) fell 16.09% year-over-year to -$1.01; the TTM figure through Dec 2025 stood at -$4.07 (down 103.5% YoY), while the FY2025 annual figure was -$4.07, down 103.5% from the prior year.
- EPS (Weighted Average and Diluted) was -$1.01 for Q4 2025 at Arcellx, down from -$0.99 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.42 in Q4 2023 to a low of -$40.78 in Q4 2021.
- Historically, EPS (Weighted Average and Diluted) has averaged -$7.89 across 5 years, with a median of -$0.9 in 2024.
- The sharpest annual moves came in 2023 and 2025: EPS (Weighted Average and Diluted) jumped 155.26% in 2023, then slumped 707.14% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$40.78 in 2021, then jumped by 98.14% to -$0.76 in 2022, then surged by 155.26% to $0.42 in 2023, then plunged by 307.14% to -$0.87 in 2024, then declined by 16.09% to -$1.01 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at -$1.01 (Q4 2025), -$0.99 (Q3 2025), and -$0.94 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | -1.01 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.01 |
| Sep 30, 2025 | -0.99 |
| Jun 30, 2025 | -0.94 |
| Mar 31, 2025 | -1.13 |
| Dec 31, 2024 | -0.87 |
| Sep 30, 2024 | -0.48 |
| Jun 30, 2024 | -0.51 |
| Mar 31, 2024 | -0.14 |
| Dec 31, 2023 | 0.42 |
| Sep 30, 2023 | -0.81 |
| Jun 30, 2023 | -0.50 |
| Mar 31, 2023 | -0.58 |
| Dec 31, 2022 | -0.76 |
| Sep 30, 2022 | -2.12 |
| Jun 30, 2022 | -0.84 |
| Mar 31, 2022 | -1.25 |
| Dec 31, 2021 | -40.78 |
| Sep 30, 2021 | -34.72 |
| Jun 30, 2021 | -36.42 |
| Mar 31, 2021 | -33.45 |